Background: Research is needed to measure the effects of shared decision-making (SDM) on discontinuation of opioid therapy for chronic pain.
Design: Target trial emulation.
Setting: National pain research registry from September 2016 to January 2024.
Participants: A total of 328 patients currently using opioid therapy for chronic low back pain at baseline, including 164 patients each in greater and lesser SDM groups matched on propensity scores.
Measurements: SDM was measured with the Communication Behavior Questionnaire. Primary outcomes involving discontinuation of opioid therapy and opioid prescribing frequency and secondary outcomes of pain, function, and health-related quality of life were measured over 12 months.
Results: The mean (SD) age of patients was 56.1 (SD, 11.1) years and 239 (72.9%) were female. During 1178 quarterly encounters, greater SDM was associated with less frequent discontinuation of opioid therapy 3 months postbaseline (RR, 0.56; 95% CI, 0.37-0.86; P = .006) and more frequent opioid prescribing 3 to 12 months postbaseline (RR, 1.24; 95% CI, 1.11-1.38: P < .001). Although greater SDM was associated with worse physical function, and opioid therapy was associated with greater back-related disability and worse physical function, these results were not clinically important. SDM x opioid therapy interaction effects were not observed, indicating that more frequent use of opioid therapy with SDM did not yield better outcomes.
Conclusions: SDM was associated with less frequent short-term discontinuation of opioid therapy and more frequent long-term opioid prescribing that was not associated with better outcomes. Thus, SDM is necessary but insufficient to improve opioid prescribing for patients with chronic pain.
Keywords: Analgesics; Chronic Pain; Communication; Low Back Pain; Opioid; Pain Management; Patient-Centered Care; Pharmacology; Physician's Practice Patterns; Propensity Score; Quality of Life; Shared Decision-Making; Surveys and Questionnaires; Target Trial Emulation Study.
© Copyright 2025 by the American Board of Family Medicine.